Robinson Osteosarcoma Fund

The Robinson Family Osteosarcoma Research Fund is backing a human clinical trial set to open at MD Anderson in October 2017.  It will use NK (natural killer) cells to target solid tumors in patients.  Immunotherapy seems to be the most promising to offer any advances in the treatment of osteosarcoma.  There have been no significant changes in the way osteosarcoma is treated since the early 1980s.

Please partner with us.  Any donation is a step forward, no matter the dollar amount.